Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (28 quarters reported)
$406M in Q4 2019 → $1.86B now. Hover for any quarter.
As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| PP Praxis Precision Medicines I | 6.7% | Added 63% | 425,000 | $124M |
| Revolution Medicines Inc | 6.6% | Trimmed 14% | 600,000 | $123M |
| Ideaya Biosciences Inc | 5.9% | Trimmed 5.0% | 2,850,000 | $109M |
| Erasca Inc | 4.7% | Trimmed 51% | 5,900,000 | $86.5M |
| AS Abivax Sa | 4.6% | Trimmed 15% | 870,000 | $86.1M |
| Cg Oncology Inc | 3.7% | Trimmed 2.5% | 975,000 | $69.1M |
| Disc Medicine Inc | 3.6% | Added 16% | 1,015,000 | $66.4M |
| Biontech Se | 3.4% | Trimmed 36% | 650,000 | $63.9M |
| Tango Therapeutics Inc | 2.9% | Trimmed 25% | 2,150,000 | $53.6M |
| Madrigal Pharmaceuticals Inc | 2.7% | New | 100,000 | $50.4M |
| Enliven Therapeutics Inc | 2.7% | Added 132% | 1,080,000 | $49.5M |
| Dyne Therapeutics Inc | 2.6% | Added 18% | 3,000,000 | $48.3M |
| Ocular Therapeutix Inc | 2.5% | Added 13% | 6,000,000 | $46M |
| Dianthus Therapeutics Inc | 2.4% | Trimmed 38% | 500,000 | $44M |
| Arrivent Biopharma Inc | 2.2% | Added 35% | 1,350,000 | $40.9M |
| Cogent Biosciences Inc | 2.2% | Added 39% | 1,250,000 | $40M |
| Erasca Inc Call | 2.0% | New | 2,500,000 | $36.7M |
| Neurocrine Biosciences Inc | 1.9% | New | 250,000 | $35.5M |
| Belite Bio Inc | 1.8% | Trimmed 20% | 200,000 | $34M |
| Axsome Therapeutics Inc. | 1.7% | New | 175,000 | $32.3M |
| Structure Therapeutics Inc | 1.7% | Added 100% | 1,000,000 | $31.3M |
| Olema Pharmaceuticals Inc | 1.5% | Unchanged | 3,208,875 | $27.7M |
| AL Achieve Life Science Inc | 1.4% | Trimmed 41% | 3,200,000 | $25.9M |
| Maze Therapeutics Inc | 1.4% | Trimmed 52% | 935,000 | $25.4M |
| PM Parabilis Medicines Inc | 1.3% | Added 43% | 750,000 | $24.2M |
| A Apnimed Inc | 1.3% | New | 1,100,000 | $24.1M |
| Yarrow Bioscience Inc | 1.2% | New | 1,026,258 | $23.1M |
| Avalo Therapeutics Inc Call | 1.2% | New | 1,500,000 | $23M |
| Trevi Therapeutics Inc | 1.1% | Trimmed 23% | 1,445,000 | $20.7M |
| Veradermics Inc | 1.1% | Trimmed 5.6% | 170,000 | $20.6M |
| Replimune Group Inc Call | 1.1% | New | 1,500,000 | $19.9M |
| VT Vera Therapeutics Inc | 1.0% | Trimmed 73% | 600,000 | $19.4M |
| Design Therapeutics Inc Call | 1.0% | New | 1,500,000 | $18.9M |
| Sarepta Therapeutics Inc Call | 1.0% | New | 1,000,000 | $18.2M |
| Sarepta Therapeutics Inc | 1.0% | New | 1,000,000 | $18.2M |
| Moonlake Immunotherapeutics | 0.9% | Trimmed 44% | 1,500,000 | $17.6M |
| Summit Therapeutics Inc Call | 0.9% | New | 1,000,000 | $16.9M |
| IH Immunocore Hldgs PLC | 0.8% | Trimmed 17% | 500,000 | $15.1M |
| Biohaven Ltd | 0.8% | New | 1,100,000 | $14.7M |
| Crispr Therapeutics Ag | 0.7% | Trimmed 17% | 250,000 | $13.8M |
| Biohaven Ltd Call | 0.7% | New | 1,000,000 | $13.4M |
| Definium Therapeutics Inc | 0.7% | Added 338% | 350,000 | $13.3M |
| Arcus Biosciences Inc Call | 0.7% | New | 500,000 | $12.9M |
| Entera Bio Ltd | 0.7% | New | 4,411,764 | $12.8M |
| Design Therapeutics Inc | 0.7% | Trimmed 67% | 1,000,000 | $12.6M |
| Compass Pathways PLC Call | 0.7% | New | 1,000,000 | $12.4M |
| Crescent Biopharma Inc. | 0.7% | Trimmed 55% | 850,000 | $12.4M |
| ET Electra Therapeutics Inc | 0.6% | New | 1,000,000 | $11.3M |
| Minerva Neurosciences Inc | 0.6% | Unchanged | 3,288,777 | $11M |
| Lb Pharmaceuticals Inc | 0.5% | Trimmed 57% | 250,000 | $9.6M |
| AL Achieve Life Science Inc Call | 0.4% | New | 1,000,000 | $8.09M |
| Alumis Inc Call | 0.4% | New | 1,000,000 | $7.39M |
| IS Inventiva Sa Call | 0.4% | New | 2,000,000 | $7.38M |
| Eyepoint Inc Call | 0.4% | New | 2,000,000 | $6.54M |
| Viking Therapeutics Inc | 0.4% | New | 200,000 | $6.52M |
| Editas Medicine Inc | 0.3% | Unchanged | 2,222,000 | $5.71M |
| TP Tonix Pharmaceuticals Hldg C | 0.3% | New | 550,000 | $5.36M |
| Opus Genetics Inc | 0.3% | New | 1,000,000 | $4.84M |
| V Vogenx Inc | 0.3% | New | 205,000 | $4.67M |
| Immunovant Inc | 0.2% | Trimmed 87% | 85,000 | $2.87M |
Showing top 60 of 72 positions.
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2026 · filed November 16, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Erasca Inc | Trimmed | −6,250,000 | −$91.6M | 4.7% |
| CT Celldex Therapeutics Inc New | Exited | −2,100,000 | −$78.1M | — |
| VT Vera Therapeutics Inc | Trimmed | −1,600,000 | −$51.7M | 1.0% |
| Madrigal Pharmaceuticals Inc | New | +100,000 | +$50.4M | 2.7% |
| PP Praxis Precision Medicines I | Added | +165,000 | +$48.1M | 6.7% |
| Erasca Inc | New | +2,500,000 | +$36.7M | 2.0% |
| Biontech Se | Trimmed | −365,000 | −$35.9M | 3.4% |
| Neurocrine Biosciences Inc | New | +250,000 | +$35.5M | 1.9% |
| Axsome Therapeutics Inc. | New | +175,000 | +$32.3M | 1.7% |
| Compass Pathways PLC | Exited | −2,250,000 | −$31.8M | — |
Showing the 10 largest of 88 changes.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Revolution Medicines Inc | Trimmed | −1,300,000 | −$243M | 5.6% |
| Biontech Se | New | +1,015,000 | +$94.4M | 4.1% |
| VT Vera Therapeutics Inc | New | +2,200,000 | +$94.4M | 4.1% |
| Centessa Pharmaceuticals PLC | Exited | −2,125,000 | −$84.4M | — |
| Terns Pharmaceuticals Inc | Exited | −1,500,000 | −$79.1M | — |
| CT Celldex Therapeutics Inc New | Added | +1,650,000 | +$61.4M | 3.4% |
| Cytokinetics Inc | Exited | −875,000 | −$57.7M | — |
| UT United Therapeutics Corp Del | Exited | −80,000 | −$47.4M | — |
| AS Abivax Sa | Added | +349,000 | +$46.5M | 5.9% |
| Madrigal Pharmaceuticals Inc | Exited | −85,000 | −$44.5M | — |
Showing the 10 largest of 85 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Revolution Medicines Inc | Exited | −1,000,000 | −$79.7M | — |
| Centessa Pharmaceuticals PLC | Added | +1,925,000 | +$76.5M | 4.2% |
| Cidara Therapeutics Inc | Exited | −310,000 | −$68.5M | — |
| UT United Therapeutics Corp Del | New | +80,000 | +$47.4M | 2.4% |
| Madrigal Pharmaceuticals Inc | New | +85,000 | +$44.5M | 2.2% |
| Terns Pharmaceuticals Inc | Added | +750,000 | +$39.5M | 3.9% |
| Cytokinetics Inc | Added | +575,000 | +$37.9M | 2.9% |
| Avidity Biosciences Inc | Exited | −500,000 | −$36.1M | — |
| Jazz Pharmaceuticals PLC | Exited | −200,000 | −$34M | — |
| AS Abivax Sa | Added | +275,000 | +$30.6M | 3.8% |
Showing the 10 largest of 77 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| PP Praxis Precision Medicines I | Added | +250,000 | +$73.7M | 6.7% |
| Akero Therapeutics Inc | Exited | −1,200,000 | −$57M | — |
| Arvinas Inc | Exited | −5,575,000 | −$47.5M | — |
| Terns Pharmaceuticals Inc | New | +750,000 | +$30.3M | 1.8% |
| Ideaya Biosciences Inc | Added | +875,000 | +$30.2M | 6.5% |
| Tango Therapeutics Inc | Added | +3,250,000 | +$28.8M | 2.2% |
| Immunovant Inc | Added | +1,100,000 | +$28M | 2.1% |
| Arcus Biosciences Inc | New | +1,050,000 | +$25M | 1.5% |
| Moonlake Immunotherapeutics | New | +1,750,000 | +$23.1M | 1.4% |
| Acadia Pharmaceuticals Inc | New | +850,000 | +$22.7M | 1.4% |
Showing the 10 largest of 73 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR Series Trust | Exited | −1,000,000 | −$82.9M | — |
| Revolution Medicines Inc | New | +1,000,000 | +$46.7M | 4.2% |
| AS Abivax Sa | New | +415,000 | +$35.2M | 3.2% |
| Jazz Pharmaceuticals PLC | Trimmed | −250,000 | −$33M | 2.4% |
| Ideaya Biosciences Inc | Trimmed | −1,095,000 | −$29.8M | 5.5% |
| Verastem Inc | Added | +3,050,000 | +$26.9M | 3.2% |
| TP Teva Pharmaceutical Inds Ltd | Exited | −1,500,000 | −$25.1M | — |
| UT United Therapeutics Corp Del | Exited | −85,000 | −$24.4M | — |
| Vaxcyte Inc | New | +625,000 | +$22.5M | 2.0% |
| Protagonist Therapeutics Inc | New | +300,000 | +$19.9M | 1.8% |
Showing the 10 largest of 66 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR Series Trust | New | +1,000,000 | +$82.9M | 9.2% |
| Jazz Pharmaceuticals PLC | New | +450,000 | +$47.8M | 5.3% |
| Nuvalent Inc | Exited | −500,000 | −$35.5M | — |
| TP Teva Pharmaceutical Inds Ltd | Exited | −1,700,000 | −$26.1M | — |
| TP Teva Pharmaceutical Inds Ltd | New | +1,500,000 | +$25.1M | 2.8% |
| Biogen Inc | New | +200,000 | +$25.1M | 2.8% |
| UT United Therapeutics Corp Del | New | +85,000 | +$24.4M | 2.7% |
| Arvinas Inc | New | +3,300,000 | +$24.3M | 2.7% |
| Xenon Pharmaceuticals Inc | Exited | −650,000 | −$21.8M | — |
| Neurocrine Biosciences Inc | New | +150,000 | +$18.9M | 2.1% |
Showing the 10 largest of 59 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cytokinetics Inc | Exited | −900,000 | −$42.3M | — |
| VT Vera Therapeutics Inc | Exited | −875,000 | −$37M | — |
| Nuvalent Inc | New | +500,000 | +$35.5M | 6.3% |
| Merus N V | Exited | −750,000 | −$31.5M | — |
| Insmed Inc | Exited | −450,000 | −$31.1M | — |
| Neurocrine Biosciences Inc | Exited | −200,000 | −$27.3M | — |
| TP Teva Pharmaceutical Inds Ltd | New | +1,700,000 | +$26.1M | 4.6% |
| Vaxcyte Inc | Exited | −300,000 | −$24.6M | — |
| Xenon Pharmaceuticals Inc | New | +650,000 | +$21.8M | 3.9% |
| Jazz Pharmaceuticals PLC | Exited | −175,000 | −$21.6M | — |
Showing the 10 largest of 46 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Disc Medicine Inc | Trimmed | −735,000 | −$46.6M | 1.5% |
| Biontech Se | New | +300,000 | +$34.2M | 4.0% |
| Insmed Inc | New | +450,000 | +$31.1M | 3.6% |
| CT Celldex Therapeutics Inc New | Exited | −900,000 | −$30.6M | — |
| Ionis Pharmaceuticals Inc | Exited | −750,000 | −$30M | — |
| Apellis Pharmaceuticals Inc | Exited | −1,000,000 | −$28.8M | — |
| Neurocrine Biosciences Inc | New | +200,000 | +$27.3M | 3.2% |
| Cytokinetics Inc | Added | +500,000 | +$23.5M | 5.0% |
| Ideaya Biosciences Inc | Added | +900,000 | +$23.1M | 9.0% |
| Galapagos Nv | Exited | −800,000 | −$23M | — |
Showing the 10 largest of 62 changes.
Loading...